Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MDR-TB

- PMLiVE

Verily unveils next-gen trials alliance with Novartis, Pfizer

New data methods and tech will be used to streamline trials

- PMLiVE

Otsuka’s Alzheimer’s agitation drug hits the mark

Drug addresses one of the most challenging symptoms in dementia care

- PMLiVE

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

The latest from pharma, biotech and healthcare

- PMLiVE

Otsuka utilises Envision Pharma Group’s medical affairs platform

The programme offers Otsuka’s stakeholders a more “user friendly” experience

- PMLiVE

Otsuka finally gets FDA OK for kidney disease drug

Approval at last for rare disease treatment

Otsuka rewards digital health startup NeuroFlow

Mental illness tech platform wins the pharma firm's US pitch challenge

- PMLiVE

Lundbeck and Otsuka start phase III for Rexulti in bipolar

Drug is also in phase II trial to treat PTSD patients

- PMLiVE

J&J expands its TB research programme

Partners with Indian groups CSIR and IMTECH to develop new treatments

- PMLiVE

Lundbeck trial failure dashes hopes in Alzheimer’s once again

Phase III trial fails to substantially improve cognition despite promising phase II data

Otsuka joins forces with IBM for Watson-based digital venture

Otsuka Digital Health will develop software to analyse psychiatric patient data

- PMLiVE

Otsuka joins its Japanese peers on Twitter

The firm's US operations make their social media debut

FDA knocks-back Otsuka’s digital pill plans

Wants more data on its combination of Abilify and Proteus sensor and pill

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links